Pregabalin · Products & formulations

Explore medicine guides

Pregabalin Brands, Forms & Strengths in the UK

Understand the available formulations of Pregabalin in the UK: 8 capsule strengths, oral liquid solution, brand names, generic equivalence, and excipients.

✓ UK prescribing context✓ Plain-language answers✓ Linked medical sources
Medical information: This page provides general educational information for people in the UK. It is not a substitute for advice from a qualified healthcare professional.

Use this guide to

01UnderstandWhat Pregabalin is used for and how it works.
02CheckDosage, interactions, side effects and warnings.
03PrepareBetter questions for your GP, pharmacist or prescriber.
Pregabalin at a glanceStart with the points most relevant to you
Original productGenuine UK-licensed medicine, supplied through the authorised pharmacy process.
Common usesNerve pain, some seizures and generalised anxiety disorder.
Key cautionDrowsiness and dizziness can affect driving and balance.
Before changing treatmentSpeak with a prescriber before reducing or stopping it.
1
Quick answer: In the United Kingdom, Pregabalin is supplied in two primary formulations: hard capsules in eight licensed strengths (25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, and 300mg) and a 20mg/ml oral liquid solution. While originally marketed under the brand name Lyrica, it is now widely prescribed across the NHS as generic Pregabalin, as well as under branded generic names including Alzain, Axalid, and Lecaent.

Master UK capsule strengths table

Each capsule strength is designed to allow precise clinical titration and tailored dosing:

StrengthCommon Clinical RoleTypical Appearance (Lyrica standard)
25mgInitial starting dose in older adults; fine dose titration; severe renal impairment dosingWhite opaque body and cap; marked "PFIZER" / "PGN 25"
50mgTitration step; starting dose in moderate kidney disease; three-times-daily dosing (150mg/day)White opaque body and cap; marked "PFIZER" / "PGN 50"
75mgStandard starting dose for adults with normal kidney function (75mg twice daily = 150mg/day)White opaque body with orange cap; marked "PGN 75"
100mgIntermediate titration step; three-times-daily dosing (300mg/day)Orange opaque body and cap; marked "PGN 100"
150mgStandard maintenance dose for neuropathic pain and anxiety (150mg twice daily = 300mg/day)White opaque body with light orange cap; marked "PGN 150"
200mgIntermediate dose for patients requiring stepped increases above 300mgLight orange opaque body and cap; marked "PGN 200"
225mgSpecialist titration dose (225mg twice daily = 450mg/day)White opaque body with orange cap; marked "PGN 225"
300mgMaximum single capsule strength; used for 600mg maximum daily dose (300mg twice daily)White opaque body with red/orange cap; marked "PGN 300"

Note: Generic capsule colour schemes and external imprint codes vary widely between manufacturers (e.g. Accord, Teva, Sandoz, Milpharm, Zentiva). Always check the milligram strength printed clearly on the pharmacy dispensing label and blister foil.

Pregabalin oral liquid solution (20mg/ml)

For patients unable to swallow solid capsules, the NHS provides a licensed oral liquid formulation:

  • Strength: 20 milligrams of Pregabalin per millilitre of liquid (20mg/ml).
  • Who it is for: Patients with dysphagia (swallowing difficulties following stroke or head/neck surgery), patients with enteral feeding tubes (nasogastric or PEG tubes), paediatric neurology patients, and adults undergoing very slow, delicate micro-tapering.
  • Accurate measurement: The bottle is supplied with an oral measuring syringe and bottle adapter. Never use a household spoon.
  • Storage after opening: Liquid bottles typically expire 4 to 6 weeks after first opening; check the packaging instructions carefully.

Lyrica vs generic Pregabalin in the NHS

Lyrica was the original trade name developed by Pfizer. When the European and UK patents expired, generic manufacturers gained approval to produce identical formulations.

What you should know about generic prescribing:

  • Bioequivalence: Under MHRA regulations, generic medicines must prove "bioequivalence"—meaning they deliver the identical active compound into the bloodstream at the identical rate and extent as the branded original.
  • NHS cost savings: Generic prescribing saves the NHS tens of millions of pounds each year. GPs in the UK are instructed to prescribe generically ("Pregabalin") by default unless there is a specific clinical reason.
  • Branded generics: Some NHS trusts purchase branded generics (such as Alzain, Axalid, or Lecaent) to ensure consistent local supply and pricing.

Inactive ingredients and lactose intolerance

While the active drug compound is identical, the inactive filler ingredients (excipients) can vary:

  • Lactose monohydrate: Almost all brands of Pregabalin hard capsules contain lactose. While the small quantity (usually 5mg to 35mg per capsule) is well tolerated by most people with mild lactose intolerance, those with severe hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption should inform their doctor.
  • Gelatine: Capsule shells are usually made from bovine or porcine gelatine. Patients requiring vegetarian, halal, or kosher medicines should consult their pharmacist; oral liquid solutions do not contain gelatine.

UK pharmacy collection and Schedule 3 rules

Because Pregabalin is a Class C Controlled Drug (Schedule 3) in the UK:

  • 28-day prescription validity: The prescription must be dispensed within 28 days of the date written.
  • Maximum supply: Prescriptions are routinely restricted to a 30-day quantity.
  • ID requirement: The pharmacist or pharmacy technician may ask for proof of identity or a signature when you collect your medicine.
  • Safe disposal: Never dispose of unwanted Pregabalin capsules in household rubbish or down the toilet. Return all unused blisters to a community pharmacy for safe destruction.

Clinical sources and references

Draft publication status: This page is prepared for a UK audience but has not yet received qualified clinical review.
Author: MediHarbour Editorial Team · Medical reviewer: To be assigned · Review date: Pending · Draft updated: 1 October 2026.
Sources should be checked against current NHS, MHRA, NICE, UK product information and peer-reviewed evidence before publication. Read our editorial policy.